How Pharma and Medtech should respond to new EU rules on R&D on biological resources

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Formidling

Standard

How Pharma and Medtech should respond to new EU rules on R&D on biological resources. / Van Vooren, Bart.

I: Scrip Regulatory Affairs, 05.2016, s. 2-5.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Formidling

Harvard

Van Vooren, B 2016, 'How Pharma and Medtech should respond to new EU rules on R&D on biological resources', Scrip Regulatory Affairs, s. 2-5.

APA

Van Vooren, B. (2016). How Pharma and Medtech should respond to new EU rules on R&D on biological resources. Scrip Regulatory Affairs, 2-5.

Vancouver

Van Vooren B. How Pharma and Medtech should respond to new EU rules on R&D on biological resources. Scrip Regulatory Affairs. 2016 maj;2-5.

Author

Van Vooren, Bart. / How Pharma and Medtech should respond to new EU rules on R&D on biological resources. I: Scrip Regulatory Affairs. 2016 ; s. 2-5.

Bibtex

@article{cfb694f1f3384eafbc911a51ea6e97ac,
title = "How Pharma and Medtech should respond to new EU rules on R&D on biological resources",
author = "{Van Vooren}, Bart",
year = "2016",
month = may,
language = "English",
pages = "2--5",
journal = "Scrip Regulatory Affairs",
issn = "2047-9727",
publisher = "Informa Healthcare",

}

RIS

TY - JOUR

T1 - How Pharma and Medtech should respond to new EU rules on R&D on biological resources

AU - Van Vooren, Bart

PY - 2016/5

Y1 - 2016/5

M3 - Journal article

SP - 2

EP - 5

JO - Scrip Regulatory Affairs

JF - Scrip Regulatory Affairs

SN - 2047-9727

ER -

ID: 162384750